In aged mice, combining the BCL-xL PROTAC PZ15227 with a USP7 inhibitor creates dual-mechanism synthetic lethality in...

IF PZ15227 (BCL-xL PROTAC, CRBN-recruiting degrader; proposed dose 10–50 mg/kg i.p., intermittent 3-days-on/4-days-off schedule based on PROTAC pharmacokinetic conventions) is administered in combination with a USP7 inhibitor (e.g., P5091 or analogous compound, 10 mg/kg i.p., co-dosed) to aged C57BL/6J male and female mice (22–24 months) — with navitoclax (ABT-263, 50 mg/kg oral gavage, same schedule) and PZ15227 monotherapy as active comparators and vehicle as negative control —

THEN the PZ15227 + USP7i combination will achieve ≥40% greater reduction in tissue senescent cell burden (p16^INK4a^, p21^CIP1^, SA-β-gal, and SASP panel: IL-6, IL-8, MMP3) compared to navitoclax monotherapy across liver, kidney, and hippocampal subgranular zone (SGZ), while maintaining platelet counts within ≤15% of vehicle-treated aged controls (vs. an expected ≥50% platelet reduction with navitoclax), measured at 4 weeks post-treatment initiation,

BECAUSE the following causal chain:

1. Senescent cells overexpress BCL-xL as a primary survival factor enabling their persistence; PZ15227 recruits cereblon (CRBN) E3 ligase to polyubiquitinate and proteasomally degrade BCL-xL specifically in nucleated cells that express adequate CRBN, eliminating the anti-apoptotic shield in senescent cells. (BCL-xL PROTAC senolytic mechanism and CRBN-dependent platelet sparing)[https://doi.org/10.1038/s41467-020-15838-0]

2. Platelets are anucleate and express low CRBN protein; PZ15227-mediated degradation requires CRBN-dependent ubiquitination, meaning platelets are structurally exempt from BCL-xL degradation even at therapeutic doses — this is the mechanistic basis of platelet sparing that distinguishes PZ15227 from navitoclax's purely inhibitory (and platelet-lethal) mechanism. (CRBN-recruiting PROTAC retains senolytic efficacy with substantially reduced platelet toxicity vs navitoclax)[https://doi.org/10.1038/s41467-020-15838-0]

3. USP7 (ubiquitin-specific protease 7) inhibition in senescent cells destabilizes MDM2, leading to p53 stabilization and transcriptional induction of pro-apoptotic effectors PUMA (BBC3), NOXA (PMAIP1), and FAS — and critically, also perturbs the BCL-xL:BH3 protein interaction, providing an independent pro-apoptotic signal that converges on the same mitochondrial pathway targeted by PZ15227. (USP7 inhibition destabilizes MDM2 → p53 → PUMA/NOXA/FAS induction, and perturbs BCL-XL interaction in senescent cells)[https://doi.org/10.1111/acel.13117]

4. USP7 inhibition selectively kills senescent cells in vitro and reduces therapy-induced senescent cell burden and SASP in vivo, validating USP7i as an independent, orthogonal senolytic mechanism already validated at the preclinical level. (USP7 inhibition selectively eliminates senescent cells in vivo, reducing SASP)[https://doi.org/10.1111/acel.13117]

5. The synthetic lethality logic: PZ15227 removes BCL-xL protein (the anti-apoptotic gatekeeper), while concurrent USP7 inhibition elevates...

SENS category: RepleniSENS

Key references: • doi.org/10.1038/s41467-020-15838-0] • doi.org/10.1111/acel.13117] • doi.org/10.1016/j.stemcr.2021.12.010] • doi.org/10.7554/elife.75492] • doi.org/10.1016/j.ebiom.2017.04.013]